By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Verastem, Inc. 

215 First Street
Suite 440
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-858-0338 Fax: n/a


Company News
Verastem, Inc. (VSTM) Receives Orphan Drug Designation From FDA For VS-5584 In Mesothelioma 2/12/2015 12:11:54 PM
Verastem, Inc. (VSTM) Announces The Grant Of Inducement Awards 2/5/2015 9:36:54 AM
Verastem, Inc. (VSTM) To Present At Upcoming Investor Conferences 2/3/2015 12:13:40 PM
Verastem, Inc. (VSTM) Announces Pricing Of Public Offering Of Common Stock 1/23/2015 10:24:09 AM
Verastem, Inc. (VSTM) Announces Proposed Public Offering Of Common Stock 1/21/2015 12:52:38 PM
Verastem, Inc. (VSTM) Doses First Patient In Phase 1 Clinical Trial Evaluating VS-5584 In Combination With VS-6063 In Mesothelioma 1/20/2015 11:04:58 AM
Verastem, Inc. (VSTM) Announces Publication Of Scientific Data For VS-5584 In Cancer Research 1/16/2015 10:12:34 AM
Verastem, Inc. (VSTM) Provides Year-End 2014 Update And Outlook For 2015 1/9/2015 11:06:39 AM
Verastem, Inc. (VSTM) To Host Conference Call And Slide Webcast On Thursday, January 8 At 4:30pm ET 1/6/2015 11:26:08 AM
Verastem, Inc. (VSTM) Appoints Daniel Paterson As Chief Operating Officer 12/18/2014 9:26:03 AM